Answers are grounded in this paper and cite their sources.
Once-daily osilodrostat effectively and safely treats patients with biochemically controlled CS, improving circadian cortisol profiles, quality of life, and sleep. Findings support further exploration of chronotherapy-based approaches in CS management.
No takes yet. Share an insight, caveat, or question.
Ferrari et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: